Prevention of acute graft-versus-host disease in adult T-cell leukemia-lymphoma patients who received mogamulizumab before allogeneic hematopoietic cell transplantation.

Yoshitaka Inoue, Nao Nishimura, Masayuki Murai, Miho Matsumoto, Miho Watanabe, Asami Yamada, Mikiko Izaki, Kisato Nosaka, Masao Matsuoka

International journal of hematology 2022 Mar

filter terms:

Mogamulizumab (Mog) is effective against adult T-cell leukemia-lymphoma (ATL), but as we reported previously, Mog increases the incidence of severe acute GVHD when administered before allogeneic hematopoietic cell transplantation (allo-HCT). Here, we report the cases of two ATL patients who did not develop acute GVHD despite receiving Mog before allo-HCT. Case 1: a 63-year-old female who underwent allo-HCT from an HLA-matched donor 2 months after the last dose of Mog. Case 2: a 47-year-old male with ATL that relapsed 3 months after first allo-HCT. He received eight doses of Mog and underwent a second allo-HCT from a haploidentical donor 4 months after the last dose of Mog. Mog blood levels were measured and lymphocytes analyzed by mass cytometry. Mog blood levels measured before starting the conditioning regimens were low. A small proportion of regulatory T cells (Tregs) was detected before and shortly after allo-HCT. When using Mog before allo-HCT, it is important to consider the number of Mog doses and the interval from the last dose of Mog to allo-HCT. Analyzing Mog blood levels and Treg counts before and after allo-HCT should also be useful. © 2021. Japanese Society of Hematology.

Citation

Yoshitaka Inoue, Nao Nishimura, Masayuki Murai, Miho Matsumoto, Miho Watanabe, Asami Yamada, Mikiko Izaki, Kisato Nosaka, Masao Matsuoka. Prevention of acute graft-versus-host disease in adult T-cell leukemia-lymphoma patients who received mogamulizumab before allogeneic hematopoietic cell transplantation. International journal of hematology. 2022 Mar;115(3):435-439